| Title |
Opportunity Number |
Funding Agency |
Deadline |
|
FY2024 Manufacturing USA Institute – AI for Resilient Manufacturing
|
2024-NIST-AI-MFGUSA-01 |
NIST |
9/30/2024 |
|
Combat Readiness-Medical Research Program - Translational Research Award (CRRP-TRA)
|
HT9425S24CRRPTRA |
USAMRAA |
9/4/2024 |
|
Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)
|
PAR-24-072 |
NIH |
10/05/2024 |
|
National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)
|
PAR-24-085 |
NIH |
10/05/2024 |
|
Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required)
|
PAR-24-086 |
NIH |
09/20/2024 |
|
Notice of Special Interest (NOSI): Promoting Data Reuse for Health Research
|
NOT-OD-24-096 |
NIH |
11/04/2024 |
|
Notice of Intent to Publish a Funding Opportunity Announcement for RNA Modifications Driving Oncogenesis (RNAMoDO; U01 Clinical Trial Not Allowed)
|
NOT-CA-24-053 |
NCI |
11/05/2024 |
|
Translational Neural Devices (R61/R33 – Clinical Trial Optional)
|
PAR-24-151 |
NIH |
July 29, 2024 |
|
Defense Medical Research and Development Program (DMRDP)
|
CDMRP Pre-Announcement |
USAMRAA |
Forecasted |
|
BRAIN Initiative: Production and distribution facilities for brain cell type-specific access reagents (U24 Clinical Trial Not Allowed)
|
RFA-MH-25-105 |
NIH |
09/30/2025 |
|
BRAIN Initiative: Scaled reagent resources for brain cell type-specific access across vertebrate species (U01 Clinical Trial Not Allowed)
|
RFA-MH-25-100 |
NIH |
12/15/2024 |
|
Notice of Intent to Publish a Funding Opportunity Announcement for RNA Modifications Driving Oncogenesis (RNAMoDO; U01 Clinical Trial Not Allowed)
|
NOT-CA-24-053 |
NCI |
09/05/2024 |
|
HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggable Proteome (R03 Clinical Trial Not Allowed)
|
PAR-24-197 |
NIH |
10/16/2024 |
|
Notice of Change: Early Expiration of NOT-NS-22-095: HEAL Initiative Notice of Special Interest (NOSI): Development and Validation of Pain-Related Models and Endpoints to Facilitate Non-Addictive Analgesic Discovery
|
NOT-NS-24-100 |
NIH |
10/18/2024 |
|
Notice of Special Interest (NOSI): NIDCR Support for Research on Understanding Phage Biology in the Oral Cavity
|
NOT-DE-24-014 |
NIH |
10/05/2024 |
|
Notice of Special Interest (NOSI): Interpersonal Communication Research to Advance Dental, Oral, and Craniofacial Health over the Lifecourse
|
NOT-DE-24-027 |
NIH |
09/07/2024 |
|
CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) Basic Research on Chemical Threats that Affect the Nervous System (R01 Clinical Trial Not Allowed)
|
PAR-24-030 |
NIH |
09/17/2024 |
|
CCRP Initiative: Chemical Threat Agent-induced Pulmonary and Ocular Pathophysiological Mechanisms (R01 Clinical Trial Not Allowed)
|
RFA-ES-24-005 |
NIH |
08/24/2024 |
|
Engineering Durable HIV Vaccine Responses (ENDURE) (R01 Clinical Trial Not Allowed)
|
RFA-AI-24-025 |
NIH |
09/09/2024 |
|
NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44 Clinical Trial Required)
|
PAR-24-099 |
NIH |
08/12/2024 |
|
NIAID Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required)
|
PAR-24-100 |
NIH |
8/12/2024 |
|
Kidney Cancer Research Program (KCRP)
|
HT942524KCRP |
USAMRAA |
Varies with award |
|
Reconstructive Transplant Research Program (RTRP)
|
HT9425-24-RTRP |
USAMRAA |
8/7/2024 |
|
Toxic Exposures Research Program (TERP)
|
HT942524TERP |
USAMRAA |
8/13/2024 |
|
Alcohol and Substance Use Disorders Research Program (ASUDRP)
|
HT942524ASUDRP |
USAMRAA |
9/10/2024 |
|
NIH Countermeasures Against Chemical Threats (CounterACT) Basic Research on Chemical Threats that Affect the Nervous System (R01 Clinical Trial Not Allowed)
|
PAR-23-027 |
NIH/NINDS/NIAID |
9/16/2024 |
|
Mechanisms of Inducing HIV Immunity in Early Life (MIEL) (U01 Clinical Trial Not Allowed)
|
RFA-AI-24-029 |
NIH/NIAID |
9/8/2024 |
|
Mechanistic Studies to Investigate the Interrelationship Between Sleep and/or Circadian Rhythms and Substance Use Disorders (R01 Basic Experimental Studies with Humans Required)
|
RFA-DA-25-044 |
NIH |
9/29/2024 |
|
Engineering of Biomedical Systems
|
PD-23-5345 |
U.S. National Science Foundation (NSF) |
Throughout the year 2024 |
|
Biosensing
|
PD-20-7909 |
U.S. National Science Foundation (NSF) |
Throughout the year 2024 |
|
Center of Excellence for Systems Modeling of Infection and Immunity across Biological Scales (U54 Clinical Trial Not Allowed)
|
NOT-AI-23-073 |
NIAID/NIH |
Forecasted |
|
Breast Cancer Research Program (BCRP)
|
HT942524BCRP |
USAMRAA |
Varies with award |
|
Biological Threat Reduction with Global Partners Broad Agency Announcement (BAA)
|
HDTRA1-24-S-0002 |
Defense Threat Reduction Agency (DTRA CTR) |
April 28, 2029 |
|
Development of Animal Models and Related Biological Materials for Research (R21 Clinical Trial Not Allowed)
|
PAR-21-167 |
NIH |
June 16, 2024; October 16, 2024 |
|
Translational Research Toward Development of a Kaposi Sarcoma Herpesvirus (KSHV) Vaccine (U01 Clinical Trial Optional
|
RFA-CA-24-006 |
NIH |
11/3/2024 |
|
HEAL Initiative: Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment (R01 Clinical Trial Not Allowed)
|
RFA-NS-22-034 |
NIH |
10/02/2024 |
|
Parkinson’s Research Program (PRP)
|
HT942524PRP |
DOD-AMRAA |
Varies with award |
|
Traumatic Brain Injury and Psychological Health Research Program (TBIPHRP)
|
HT942524TBIPHRP |
DOD-AMRAA |
Varies with award |
|
Peer Reviewed Orthopaedic Research Program (PRORP)
|
HT942524PRORP |
DOD-AMRAA |
Varies with award |
|
Melanoma Research Program (MRP)
|
HT942524MRP |
DOD-AMRAA |
7/29/2024 |
|
Duchenne Muscular Dystrophy Research Program (DMDRP)
|
HT942524DMDRP |
DOD-AMRAA |
8/1/2024 |
|
Peer Reviewed Cancer Research Program (PRCRP)
|
HT942524PRCRP |
DOD-AMRAA |
Varies with award |
|
ARPA-H Health Science Futures Office Innovative Solutions Opening (ISO)
|
ARPA-H-SOL-24-104 |
ARPA-H |
3/15/2025 |
|
ARPA-H Resilient Systems Office Office-wide Innovative Solutions Opening (ISO)
|
ARPA-H-SOL-24-103 |
ARPA-H |
3/15/2025 |
|
Prostate Cancer Research Program (PCRP)
|
HT942524PCRP |
DOD-AMRAA |
Varies with award |
|
Pancreatic Cancer Research Program (PCARP)
|
HT9425-24-PCARP |
DOD-AMRAA |
Varies with award |
|
Autism Research Program (ARP)
|
HT942524ARP |
DOD-AMRAA |
Varies with award |
|
Multiple Sclerosis Research Program (MSRP)
|
HT942524MSRP |
DOD-AMRAA |
Varies with award |
|
Rare Cancers Research Program (RCRP)
|
HT942524RCRP |
DOD-AMRAA |
Varies with award |
|
Alcohol and Substance Use Disorders Research Program (ASUDRP)
|
CDMRP Pre-Announcement |
DOD-AMRAA |
Forecasted |
|
Ovarian Cancer Research Program (OCRP)
|
HT942524OCRP |
DOD-AMRAA |
Varies with award |
|
Spinal Cord Injury Research Program (SCIRP)
|
CDMRP Pre-Announcement |
CDMRP Pre-Announcement |
Forecasted |
|
Hearing Restoration Research Program (HRRP)
|
CDMRP Pre-Announcement |
CDMRP Pre-Announcement |
Forecasted |
|
Lung Cancer Research Program (LCRP)
|
CDMRP Pre-Announcement |
CDMRP Pre-Announcement |
Forecasted |
|
Amyotrophic Lateral Sclerosis Research Program (ALSRP)
|
CDMRP Pre-Announcement |
DOD-AMRAA |
Forecasted |
|
Peer Reviewed Alzheimer's Research Program (PRARP)
|
CDMRP Pre-Announcement |
DOD-AMRAA |
Forecasted |
|
Epilepsy Research Program (ERP)
|
CDMRP Pre-Announcement |
DOD-AMRAA |
Forecasted |
|
HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)
|
RFA-NS-24-019 |
NIH |
1/8/2027 |
|
Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01 Clinical Trial Not Allowed)
|
PAR-24-036 |
NIH |
11/3/2026 |
|
Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R61 Clinical Trial Required)
|
PAR-24-035 |
NIH |
11/3/2026 |
|
Notice of Special Interest (NOSI): Chronic Inflammation of the Oral Cavity - An Agent for Oral Mucosal Disease
|
NOT-DE-23-007 |
NIH |
5/10/2027 |
|
Notice of Special Interest (NOSI): Using Targeted Degradation of Protein and non-Protein Targets for the Development of Novel Anti-Infectives
|
NOT-AI-23-076 |
NIH |
7/17/2026 |
|
Broad Agency Announcement (BAA) for the Protection of Deployed Military Personnel From Threats Posed by Arthropod Disease Vectors
|
AFPMB-BAA-24-01 |
DoD |
10/19/2028 |
|
2024 Human Exploration Research Opportunities (HERO) Overview
|
80JSC024NA001 |
NASA Johnson Space Center |
10/30/2024 |
|
Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)
|
BAA-23-100-SOL-00004 |
HHS/BARDA-ASPR |
10/10/2028 |
|
BRAIN Initiative: New Concepts and Early-Stage Research for Recording and Modulation in the Nervous System (R21) (Clinical Trial Not Allowed)
|
RFA-EY-23-001 |
NIH |
6/16/2026 |
|
US Special Operations Command - Broad Agency Announcement for Extramural Biomedical Research and Development
|
HT9425-23-S-SOC1 |
DOD-AMRAA |
7/31/2028 |
|
United States Army Research Institute for the Behavioral And Social Sciences (ARI) BAA for Basic, Applied, And Advanced Scientific Research
|
W911NF-23-S-0010 |
DOD-AMC |
4/30/2028 |
|
Orthopaedic Research and Education Foundation (OREF)
|
various |
OREF |
varies with award |
|
Notice of Special Interest (NOSI): Advancing Research for Tickborne Diseases (TBDs)
|
NOT-AI-23-013 |
NIH |
1/8/2026 |
|
Large Research Projects for Prevention of Healthcare-Associated Infections (R01)
|
PA-21-265 |
NIH |
5/27/2025 |
|
Large Research Projects for Combating Antibiotic-Resistant Bacteria (CARB) (R01)
|
PA-22-047 |
NIH |
10/31/2026 |
|
Large Health Services Research Demonstration and Dissemination Projects for Combating Antibiotic-Resistant Bacteria (CARB)(R18)
|
PA-22-048 |
NIH |
10/31/2026 |
|
Notice of Special Interest (NOSI): Complement in Fundamental Immunology
|
NOT-AI-23-012 |
NIH |
1/8/2026 |
|
Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional)
|
PAR-22-243 |
NIH |
9/8/2025 |
|
Engineering Next-Generation Human Nervous System Microphysiological Systems (R21 Clinical Trials Not Allowed)
|
PAR-23-047 |
NIH |
1/8/2026 |
|
Notice of Special Interest (NOSI): Halting Tuberculosis (TB) Transmission
|
NOT-AI-22-064 |
NIH |
1/8/2026 |
|
Bioengineering Research Grants (BRG) (R01 Clinical Trial Not Allowed)
|
PAR-22-242 |
NIH |
9/8/2025 |
|
Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional)
|
PAR-22-243 |
NIH |
9/8/2025 |
|
CCRP Initiative: Countermeasures Against Chemical Threats (CounterACT) Therapeutics Discovery and Early Stage Development (UG3/UH3 Clinical Trial Not Allowed)
|
PAR-22-209 |
NIH (NINDS, NEI, NIDA, NIEHS) |
10/18/2024 |
|
DoD USAMRDC FY23-FY27 Broad Agency Announcement for Extramural Medical Research
|
HT9425-23-S-BAA1 |
DOD-AMRAA |
9/30/2027 |
|
Broad Agency Announcement Research and Development In Support of The Joint Program Executive Office For Chemical, Biological, Radiological And Nuclear Defense (JPEO-CBRND), JPM MEDICAL AND JPL EB
|
W911SR-22-R-CBRN |
DOD |
6/26/2027 |
|
CCRP Initiative: Countermeasures Against Chemical Threats (CounterACT) Therapeutics Discovery and Early-Stage Development (UG3/UH3 Clinical Trial Not Allowed)
|
PAR-22-209 |
NIH |
10/18/2024 |
|
Focused Technology Research and Development (R01 Clinical Trial Not Allowed)
|
PAR-22-127 |
NIH (NIGMS, NIA, NCI) |
5/8/2025 |
|
Technology Development Research for Establishing Feasibility and Proof of Concept (R21 - Clinical Trial Not Allowed)
|
PAR-22-126 |
NIH (NIGMS, NIA, NCI) |
5/8/2025 |
|
Prospective Observational Comparative Effectiveness Research in Clinical Neurosciences (UG3/UH3 Clinical Trial Not Allowed)
|
PAR-22-076 |
NIH (NINDS) |
5/8/2025 |
|
Notice of Special Interest (NOSI): The Influence of Host Resilience on Heterogeneity of Acute Respiratory Distress Syndrome/Acute Lung Injury (ARDS/ALI)
|
NOT-HL-20-814 |
NIH (NHLBI) |
12/21/2024 |
|
Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)
|
RFA-HL-23-010 |
NIH (NHLBI) |
12/21/2024 |
|
Catalyze: Product Definition – Device Prototype Design and Testing, Diagnostic Disease Target Identification and Assay Development, and Research Tool Development (R61/R33 - Clinical Trial Not Allowed)
|
RFA-HL-23-013 |
NIH (NHLBI) |
12/21/2024 |
|
Catalyze: Product Definition – Device Prototype Testing and Design Modification, Diagnostic Disease Target Assay Development and Design Characterization, and Research Tool Testing and Validation (R33 - Clinical Trials Not Allowed)
|
RFA-HL-23-014 |
NIH (NHLBI) |
12/22/2024 |
